Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin presents on the company's lead drug candidate OPT-302 for the treatment of wet age-related macular degeneration and diabetic macular edema.Key points:- Novel technology and therapy for eye disease
- OPT-302, a new approach for the treatment of wet AMD and DME
- Market opportunity >USD$10 billion worldwide
- Safety of OPT-302
- Evidence of improved vision and reductions in fluid
- Currently enrolling patients in two randomised, controlled clinical trials
- Phase 2b wet AMD and Phase 1b/2a DME studies
- Trials are recruiting patients in US, EU, Israel and Australia
For more, watch the Managing Director and CEO Dr Megan Baldwin, present.
